SIETES :: 93213 citas

Resultados de la búsqueda por FACTORES DE CRECIMIENTO REFINAR BÚSQUEDA

1.

Anónimo. FDA approval of cenegermin marks three firsts in drug history . DIA Daily 2018:24 de agosto. [Ref.ID 102813]

2.

Lyman GH, Zon R, Harvey RD, Schilsky RL. Rationale, opportunities, and reality of biosimilar medications. N Engl J Med 2018;378:24 de mayo. [Ref.ID 102636]

3.

Poewe W, Seppi K. Insulin signalling: new target for Parkinson's treatments?. Lancet 2017;390:1628-30. [Ref.ID 102093]

4.

Scarlett JM, Rojas JM, Matsen ME, Kaiyala KJ, Stefanovski D, Bergman RN, Nguyen HT, Dorfman MD, Lantier L, Wasserman DH, Mirzadeh Z, Unterman TG, Morton GJ, Schwartz MW. Central injection of fibroblast growth factor 1 induces sustained remission of diabetic hyperglycemia in rodents.. Nat Med 2016;22:800-6. [Ref.ID 100568]

5.

Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong Y-N, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016;387:2008-16. [Ref.ID 100296]

6.

Anónimo. Zarxio - A filgrastim biosimilar. The Medical Letter on Drug and Therapeutics Bulletin 2016;58:34-5. [Ref.ID 100139]

7.

Anónimo. Pharmaceutical giant’s plea to block rival’s filgrastim biosimilar rejected. DIA Daily 2015:20 de marzo. [Ref.ID 98863]

8.

Smith MEB, Totten A, Hickam DH, Fu R, Wasson N, Rahman B, Motu'apuaka M, Saha S. Pressure ulcer treatment strategies: a sytematic comparative effectiveness review. Ann Intern Med 2013;159:39-50. [Ref.ID 95856]

9.

Bell KJ, Fulcher ML, Rowlands DS, Kerse N. Impact of autologous blood injections in treatment of mid-portion Achilles tendinopathy: double blind randomised controlled trial. BMJ 2013;346:12. [Ref.ID 95530]

10.

Maffulli N. Autologous blood products in musculoskeletal medicine. BMJ 2013;346:9. [Ref.ID 95529]

11.

McCarthy M. US firm accused of manipulating journal articles and paying millions to authors of sponsored studies. BMJ 2012;345:6. [Ref.ID 93999]

12.

Helgeson MD, Lehman RA Jr, Patzkowski JC, Dmitriev AE, Rosner MK, Mack AW. Adjacent vertebral body osteolysis with bone morphogenetic protein use in transforaminal lumbar interbody fusion. The Spine Journal 2011;11:507-10. [Ref.ID 91142]

13.

Dmitriev AE, Lehman RA Jr, Symes AJ. Bone morphogenetic protein-2 and spinal arthrodesis: the basic science perspective on protein interaction with the nervous system. The Spine Journal 2011;11:500-5. [Ref.ID 91141]

14.

Howard JM, Glassman SD, Carreon LY. Posterior iliac crest pain after posterolateral fusion with or without iliac crest graft harvest. The Spine Journal 2011;11:534-7. [Ref.ID 91140]

15.

Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. The Spine Journal 2011;11:471-91. [Ref.ID 91139]

16.

Carragee EJ, Granayem AJ, Weiner BK, Rothman DJ, Bono CM. A challenge to integrity in spine publications: years of living dangerously with promotion of bone growth factors. The Spine Journal 2011;11:463-8. [Ref.ID 91138]

17.

Ge ZZ, Chen HM, Gayo YJ, Liu WZ, Xu CH, Tan HH, Chen HY, Wei W, Fang JY, Xiao SD. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology 2011;141:1629-37. [Ref.ID 91114]

18.

Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med 2011;364:535-41. [Ref.ID 90172]

19.

Deeken JF, Winer LM. Supportive treatments for oncology patients: not just icing on the cake. Ann Intern Med 2010;153:411-2. [Ref.ID 89395]

20.

Vadhan-Raj S, Trent J, Patel S, Zhou X, Johnson MM, Araujo D, Ludwig JA, O'Roark S, Gillenwater AM, Bueso-Ramos C, El-Naggar AK, Benjamin RS. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer. A randomized trial. Ann Intern Med 2010;153:358-67. [Ref.ID 89392]